Clinical trials: Alzheimer's Dementia
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- DAYBREAK-ALZ (NCT02783573)
- Testing
- Lanabecestat
- Where
- 262 sites in United States, Canada and 16 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Alzheimer Disease, Early Onset
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and…
- Trial name
- ART-AD (NCT04552795)
- Testing
- 3TC
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimer Disease
Nutrition Interventions for Cognitive Enhancement
By doing this study, researchers hope to learn how the Mediterranean and low-fat eating patterns affect memory, brain volume, brain antioxidant status and cardio-metabolic biomarkers, such as blood pressure and blood glucose, in…
- Trial name
- NICE (NCT03841539)
- Testing
- Mediterranean Diet, Study Supplement, Low-fat Diet
- Where
- United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Alzheimer Disease, Dementia
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT04640077
- Testing
- No Intervention, donanemab
- Where
- 27 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease
Memesto Wearable Device for Persons With Dementia
An estimated 70% of the 7.2+ million people in the U.S. with Alzheimer's Disease and Alzheimer's Disease-Related Dementias experience agitation, characterized by poorly organized and purposeless psychomotor activity that…
- Trial name
- NCT05153161
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Edgewater Safety Systems, Inc.
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
MR Guided tDCS in Alzheimer's Disease
The purpose of the study is to investigate the effect of High Density- tDCS (HD- tDCS) on cognitive function in Alzheimer's Disease.
- Trial name
- NCT03325205
- Testing
- Anodal tDCS
- Where
- Norway
- Volunteers
- 19 people
- Sponsor
- University of Tromso
Dementia, Alzheimer's Disease
In-Home Technology for Dementia Caregivers
This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal…
- Conditions
- Dementia, Alzheimer's Disease, Frontotemporal Dementia
- Trial name
- NCT03828383
- Testing
- In-home technology, Limited in-home technology
- Where
- 5 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer Disease, Dementia, Mild
Paper-Based and Smartphone-Based Memory Supports
Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT06444841
- Testing
- Digital - Google Calendar, Paper-based - Memory Support System
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Baylor University
Alzheimer Disease, Dementia
Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias
The estimated annual cost of dementia in Canada is $15 billion, with a projected cumulative economic burden of $800 billion by 2038.
- Trial name
- BIMII (NCT03035851)
- Testing
- Aerobic exercise, Stretch and Strength
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- University of Calgary
Alzheimer Disease
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer…
- Trial name
- NCT00479219
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease
ETNA3 is a multicentric randomised clinical trial conducted in France to evaluate the impact of cognitive training, reminiscence therapy and a "made-to-measure" program on the progression rate of dementia.
- Trial name
- ETNA3 (NCT00646269)
- Testing
- Standard intervention protocol, Standard intervention protocol + Cognitive training therapy, Standard intervention protocol + Reminiscence therapy
- Where
- 39 sites in France
- Volunteers
- 640 people
- Sponsor
- University Hospital, Bordeaux
Mild Cognitive Impairment (MCI)
Yizhi Baduanjin for Patients With Cognitive Impairment
The trial is designed to examine whether Yizhi Baduanjin could slow down and improve in memory, logical thinking and cerebral function in patients with mild cognitive impairment (MCI).
- Trial name
- NCT06453941
- Testing
- Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)
- Where
- Hong Kong
- Volunteers
- 1 people
- Sponsor
- The University of Hong Kong
Mild Cognitive Impairment, Alzheimer's Disease
BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)
Mild Cognitive Impairment (MCI) represents a group of persons who are at risk of incident dementia in the near-term. Persons with MCI who have deficits in short-term recall (amnestic MCI) are at significant risk of incident…
- Trial name
- BDPP (NCT02502253)
- Testing
- grape seed polyphenolic extract, resveratrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University
Alzheimer's Disease
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
The study will investigate the possibility of detecting early signs of Alzheimer's disease using magnetic resonance imaging (MRI).
- Trial name
- NCT00413621
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.